16/06/2026 Avalo Therapeutics added AVTX-010, a long-acting next-generation anti-IL-1β antibody, to Its development pipeline Avalo Therapeutics added AVTX-010, a long-acting next-generation anti-IL-1β antibody, to Its development pipeline (Ref) Avalo Therapeutics announced the advancement of AVTX-010 (anti-IL-1β mAb) with the potential for development in hidradenitis suppurativa (HS) as well as additional inflammatory disorders. The Company expected to submit an Investigation

05/05/2026 J&J announced Phase 2b data from two studies in IBD J&J announced Phase 3 results for guselkumab in CD Avalo Therapeutics announced positive Phase 2 results for abdakibart in HS J&J announced Phase 2b data from two studies in IBD (Ref) Johnson & Johnson announced data from two Phase 2b studies, DUET-UC/ NCT05242484 and DUET-CD/ NCT05242471, which evaluated JNJ-4804 (IL-23 and TNF-α) in patients with moderately to severely active ulcerative colitis (UC) and Crohn’s